The McFall Lab
Publications
The publications within the last eight years have given way to breakthroughs in metabolic pathways, PDAC TME's, drug treatments, therapies, etc. What we know most is this field is ever changing and we are on a mission to combat that with basic science approaches in collaboration with some valuable statistics.
A systems mechanism for KRAS mutant allele–specific responses to targeted therapy
CRC EGFR's are responsive to certain inhibitors in KRAS mutant patients
Controversial approaches point to breakthroughs in certain patient treatment
Genomic therapy is going to pave the way for future cancer therapies
Discernment between candidate mechanisms for KRAS G13D colorectal cancer sensitivity to EGFR inhibitors
Recent discovery of drug sensitivity in patients with KRAS G13D
Using a wildtype RAS is proposed to give way to better response of inhibition
Other isoforms of G12 KRAS would be good subjects for further research
Identification of RAS mutant biomarkers for EGFR inhibitor sensitivity using a systems biochemical approach
EGFR inhibitors have been found to be really effective for certain CRC patients
NF1 binding affinity is critical for the proliferation of these CRC cells
Emergence of differences in structural biology of these mutations may open new conclusions
Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma
Microenvironment of PDAC is indicative of the type of treatment administered
Certain patients under classical and classical adjacent PDAC suffer from the worst prognosis
Knowing the PDAC TME is dynamic gives limitations but puts us on the right track for future clinical trials